BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Gastric cancer AND CCNE1, CCNE, 898, ENSG00000105173, P24864 AND Treatment
22 results:

  • 1. [Preliminary Investigation of the Molecular Mechanism of Empagliflozin Suppressing gastric cancer Through Mammalian Target of Rapamycin].
    Rao H; Cheng W; Yu J; An X; Deng H; Zhang Z; Wu F; Ji F; Li S
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 54(6):1146-1153. PubMed ID: 38162062
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.
    Jing X; Luo Z; Wu J; Ye F; Li J; Song Z; Zhang Y; Shi M; Sun H; Fang Y; Jiang Y; Ji X
    Cancer Med; 2023 Dec; 12(24):21905-21919. PubMed ID: 38050871
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Clinicopathological and prognostic features of Borrmann type IV gastric cancer versus other Borrmann types: A unique role of signet ring cell carcinoma.
    Liang C; Liang Y; Ou B; Yuan L; Yuan S
    Saudi J Gastroenterol; 2023; 29(4):240-250. PubMed ID: 37470667
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial.
    Hu Q; Oki E; Yamada T; Kashiwada T; Sonoda H; Kataoka M; Kawanaka H; Tsuji Y; Makiyama A; Nakashima Y; Ota M; Kimura Y; Yoshizumi T
    Cancer Med; 2023 Aug; 12(15):16649-16660. PubMed ID: 37325934
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing cancers.
    DiPeri TP; Evans KW; Raso MG; Zhao M; Rizvi YQ; Zheng X; Wang B; Kirby BP; Kong K; Kahle M; Yap TA; Dumbrava EE; Ajani JA; Fu S; Keyomarsi K; Meric-Bernstam F
    Clin Cancer Res; 2023 Nov; 29(21):4385-4398. PubMed ID: 37279095
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Two decades of gastric and gastroesophageal junction cancer surgery.
    Plum PS; Pamuk A; Barutcu AG; Mallmann C; Niesen E; Berlth F; Zander T; Chon SH; Moenig SP; Quaas A; Bruns CJ; Hoelscher AH; Alakus H
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7679-7688. PubMed ID: 37000260
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment.
    Kwon HJ; Park Y; Nam SK; Kang E; Kim KK; Jeong I; Kwak Y; Yoon J; Kim TY; Lee KW; Oh DY; Im SA; Kong SH; Park DJ; Lee HJ; Kim HH; Yang HK; Lee HS
    Cancer Med; 2023 May; 12(9):10371-10384. PubMed ID: 36916290
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Lycopene suppresses gastric cancer cell growth without affecting normal gastric epithelial cells.
    Zhou Y; Fu R; Yang M; Liu W; Tong Z
    J Nutr Biochem; 2023 Jun; 116():109313. PubMed ID: 36871837
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Immunohistochemical and molecular analysis of an α-fetoprotein-producing cervical adenocarcinoma with clear cell morphology.
    Kuriyama S; Yano M; Kusaba T; Zaitsu S; Nishida H; Yasuda M; Nasu K
    Med Mol Morphol; 2023 Mar; 56(1):20-27. PubMed ID: 36183278
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Defining and Targeting Esophagogastric cancer Genomic Subsets With Patient-Derived Xenografts.
    Moy RH; Walch HS; Mattar M; Chatila WK; Molena D; Strong VE; Tang LH; Maron SB; Coit DG; Jones DR; Hechtman JF; Solit DB; Schultz N; de Stanchina E; Janjigian YY
    JCO Precis Oncol; 2022 Feb; 6():e2100242. PubMed ID: 35138918
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets.
    Lu J; Ding Y; Chen Y; Jiang J; Chen Y; Huang Y; Wu M; Li C; Kong M; Zhao W; Wang H; Zhang J; Li Z; Lu Y; Yu X; Jin K; Zhou D; Zhou T; Teng F; Zhang H; Zhou Z; Wang H; Teng L
    Nat Commun; 2021 Jun; 12(1):3946. PubMed ID: 34168152
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Deep Targeted Sequencing and Its Potential Implication for cancer Therapy in Chinese Patients with gastric Adenocarcinoma.
    Yu P; Wang Y; Yu Y; Wang A; Huang L; Zhang Y; Liu W; Wu H; Yao M; Du YA; Cheng X
    Oncologist; 2021 May; 26(5):e756-e768. PubMed ID: 33511732
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Research on the Potential Mechanism of Gentiopicroside Against gastric cancer Based on Network Pharmacology.
    Huang Y; Lin J; Yi W; Liu Q; Cao L; Yan Y; Fu A; Huang T; Lyu Y; Huang Q; Wang J
    Drug Des Devel Ther; 2020; 14():5109-5118. PubMed ID: 33262572
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Influence of different biological behaviors on prognosis of patients with advanced gastric cancer at the same TNM stage].
    Gong YB; Zhu Z; Wang X; Xu HM
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Oct; 23(10):953-962. PubMed ID: 33053990
    [No Abstract]    [Full Text] [Related]  

  • 15. Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.
    Jammula S; Katz-Summercorn AC; Li X; Linossi C; Smyth E; Killcoyne S; Biasci D; Subash VV; Abbas S; Blasko A; Devonshire G; Grantham A; Wronowski F; O'Donovan M; Grehan N; Eldridge MD; Tavaré S; ; Fitzgerald RC
    Gastroenterology; 2020 May; 158(6):1682-1697.e1. PubMed ID: 32032585
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Identification and external validation of a novel miRNA signature for lymph node metastasis prediction in submucosal-invasive gastric cancer patients.
    Ma M; Lu S; Liu Y; Kong P; Long Z; Wan P; Zhang Y; Wang Y; Xu D
    Cancer Med; 2019 Oct; 8(14):6315-6325. PubMed ID: 31486298
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention: a randomized controlled trial.
    Choi JM; Kim SG; Choi J; Park JY; Oh S; Yang HJ; Lim JH; Im JP; Kim JS; Jung HC
    Gastrointest Endosc; 2018 Sep; 88(3):475-485.e2. PubMed ID: 29800546
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.
    Kim ST; Banks KC; Pectasides E; Kim SY; Kim K; Lanman RB; Talasaz A; An J; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Park SH; Park JO; Park YS; Lim HY; Kim NKD; Park W; Lee H; Bass AJ; Kim K; Kang WK; Lee J
    Ann Oncol; 2018 Apr; 29(4):1037-1048. PubMed ID: 29409051
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Diagnostic performance of conventional endoscopy in the identification of submucosal invasion by early gastric cancer: the "non-extension sign" as a simple diagnostic marker.
    Nagahama T; Yao K; Imamura K; Kojima T; Ohtsu K; Chuman K; Tanabe H; Yamaoka R; Iwashita A
    Gastric Cancer; 2017 Mar; 20(2):304-313. PubMed ID: 27165641
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer.
    Lee JY; Hong M; Kim ST; Park SH; Kang WK; Kim KM; Lee J
    Sci Rep; 2015 Mar; 5():9289. PubMed ID: 25786580
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.